52 results about "HERG" patented technology

The present invention provides a computational model and methods of use thereof for predicting whether a compound is likely to inhibit K+ flow through the hERG ion channel. Methods for in silico screening of compounds that have a lower likelihood of inhibiting hERG are also provided.

Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and / or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.

Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.

A cluster is provided comprising cardiomyocyte-like cells, wherein the cluster has i) contracting cells, ii) cells that are electrically connected, and expresses iii) cardiac markers including Nkx.2.5, troponin and myosin, iv) markers for functional adrenergic receptors, v) markers for functional muscarinic receptors, vi) markers for functional ion-channels including hERG, Na+, Ca2+ and K+ channels, vii) one or more endodermal markers selected from the group consisting of AFP, TF, APOA2, AHSG, SERPINA1, APOA1, APOC3, TTR1 APOB, and RBP4. A method for preparing the clusters and methods utilizing the clusters in drug discovery and toxicity screenings are described.

Materials, methods and a computer system are provided which facilitate the identification and characterization of modulators of potassium ion channels, particularly the HERG channel.

The invention relates to a benzimidazole hERG potassium ion channel small-molecular fluorescent probe and a preparation method and applications thereof; the fluorescent probe has the structural general formula represented by the formula (I), wherein in the formula, R1 is hydroxyl, halogen, alkyl or alkoxy monosubstituent or polysubstituent, R2 is fluorophore, n is 1-6, particularly, R1 is p-halogen, and R2 is coumarin, naphthalene diimide, NBD, Cy5 or fluorescein isothiocyanate fluorophore. The invention discloses the applications of the probe in marking of hERG potassium ion channels and high-expression tumor cells or tissues, high-throughput screening of hERG potassium ion channel inhibitors, evaluation of new drug cardiotoxicity, use as a probe for identification of the hERG potassium ion channels and studies on hERG potassium ion channel physiological, pathological and related diseases.

The invention discloses an application of chiral chloroquine, hydroxychloroquine or pharmaceutically acceptable salts of the chiral chloroquine and hydroxychloroquine in preparation of drugs used forpreventing and / or treating coronavirus pneumonia by using a coronavirus key drug target 3CL hydrolase (Mpro) as an action target. The chiral chloroquine and hydroxychloroquine have high bonding strength with the Mpro causing inflammation of the lung and the like; the activity of the Mpro can be significantly inhibited; and the chiral chloroquine and hydroxychloroquine are indicated to have the effect of preventing and treating pneumonia caused by coronaviruses and be able to be used as anti-pneumonia drugs. Through evaluation on the inhibitory activity of an hERG potassium ion channel, the concentration at which the chloroquine, hydroxychloroquine and enantiomers of the chloroquine and hydroxychloroquine are likely to generate cardiotoxicity to the hERG potassium ion channel is provided. The chiral chloroquine and hydroxychloroquine are prepared through chiral high-performance liquid chromatography and chiral synthesis; S-configuration chloroquine, hydroxychloroquine or salts of the chloroquine and hydroxychloroquine can be selected as a drug independently, or form a pharmaceutical composition for treating diseases caused by the coronaviruses; and due to higher activity and low cardiotoxicity of the chloroquine, hydroxychloroquine or salts of the chloroquine and hydroxychloroquine, the administration dosage range is greatly widened.

Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.

The present invention provides compounds of general formula I, isomers thereof, non-toxic pharmaceutically acceptable salts or solvates thereof. The compounds have remarkably strengthened analgesic activity, reduce the acute toxicity obviously, have no inhibition to heart Herg channel, and reduce side effects on coordination movement of mice remarkably. The present invention realizes the separation of activity and side effects, and has a good application prospect.

The invention relates to a method for screening hERG potassium ion channel agonist and detecting toxicity. Particularly, the invention firstly relates to a fusion protein, which contains a fragment (which is used as the N end of the fusion protein, is from a position between 1st to 85th amino acid residues of the N end of the nemathelminth ERG family potassium ion channels UNC-103 protein and has the length of 75 to 85 amino acid residues), hERG or a fragment at least containing S1-S6 transmembrane domains and cyclic nucleotide binding domains, and a fragment (which is used as the C end of the fusion protein, is from a position between 590th to 829th of amino acid residues of the C end of the UNC-103 protein and has the length of 220 to 240 amino acid residues). The invention also relates to a polynucleotide sequence coding the fusion protein, a relevant transgenic nemathelminth, a relevant screening method and application. The inventor builds an in-vivo hERG-intracellular-transport-influence-recognizable compound molecule screening method for screening hERG inhibitors or LQTS (long QT syndrome) relevant channel mutant functional correcting agents for the first time; the novel path and method are provided for hERG toxicity detection and LQTS treatment medicine screening.

The invention discloses a graph attention mechanism transfer learning-based small molecule drug hERG toxicity prediction method and device; the method comprises the following steps: S1, data set preprocessing: enabling a to-be-detected drug-like compound to generate a fingerprint sequence through molecular fingerprint generation software; s2, acquiring atom and chemical bond characteristics through the fingerprint sequence generated in the step S1, and constructing a molecular graph and graph characteristics through the atom and chemical bond characteristics; s3, processing the molecular map obtained in the step S2 through a map attention mechanism, and generating a feature vector of each atom in the molecule; s4, generating a molecular feature vector through a graph attention mechanism and the feature of each atom. According to the method, a molecular graph structure is processed based on a graph attention mechanism, a substructure which contributes to a predicted attribute value is effectively obtained, and a source domain data set and a target domain data set are processed based on transfer learning; and thereby, the problem that the sample size is insufficient is effectively solved.

It is an object of the present invention to establish a method of establishing a cell with a remarkably high hERG channel expression level for use in predicting adverse effects based on hERG channel inhibition in research and development of drugs, and to thereby establish a highly sensitive and high throughput evaluation method. By inserting a hERG gene into a retrovirus vector plasmid or lentivirus vector plasmid to thereby prepare a virus vector, concentrating the vector by ultracentrifugation if necessary, transferring the hERG gene into cells and expressing hERG channels therein, it has become possible to secure an expression level effective in measurements using a fully automated high throughput patch clamp system or dyes.

Methods for reducing toxicity or side effects caused by administration of a rycal compound for repairing ryanodine receptor channel leaks when treating a disorder in a subject caused by such leaks. These methods are based upon the selection for administration of those rycal compounds having properties including an EC50 value of 102 nM when assayed for its ability to facilitate the rebinding of FKBP12.6 to PKA-phosphorylated RyR2 or less and less than 50% inhibition of the hERG K+ channel (IKr) when administered at 10 μM to reduce compound toxicity or side effects after administration compared to other rycal compounds not having those properties.

The invention relates to the field of medicine, in particular to a tetrahydroisoquinoline derivative and a preparation method and medical application thereof. Compared with the prior art, the compoundprovided by the invention has better SERD activity and also has the following advantages: (1) the initial safety of the compound provided by the invention is superior to that of the existing tetrahydroisoquinoline SERD compound; (2) animal in-vivo experimental data show that the pharmacokinetic parameters AUC and Cmax of the compound disclosed by the invention are obviously higher than those of the existing tetrahydroisoquinoline SERD compound under the same dosage; and (3) the compound provided by the invention has relatively low hERG safety risk. Therefore, the compound disclosed by the invention has better PK property, so that reasonable prediction can be realized, the effective dose of the compound is lower when the compound is applied to clinical use, and the medication safety is higher.

The invention provides a triazole compound as well as a preparation method and medical application thereof. The triazole compound has a structure as shown in a formula (I). The triazole compound as shown in the formula (I) or pharmaceutically acceptable salts, compound salts, prodrugs, tautomers, stereoisomers or stereoisomer mixtures of the triazole compound are claimed in the invention. The compound disclosed by the invention has remarkable activity of antagonizing a histamine H1 receptor, lower M-choline side effect and lower Herg toxicity.

The invention discloses a culture method for improving hERG-HEK293 cell stability in a patch clamp test, and belongs to the field of cell culture. According to the method, by increasing the content ofFBS in the culture medium to 20% v / v and optimizing the operation steps of passage digestion, the stability of hERG-HEK293 cells in the patch clamp test can be improved, and then the success rate ofthe patch clamp test is increased.

The present invention relates to generating hiPSC-derived cardiomyocytes and embryoid bodies that recapitulate the disease phenotype of Long QT Syndrome and their use in developing pharmacological treatments thereof. The present invention also includes the use of a compound which inhibits the ubiquitin-proteasome pathway for the preparation of a medicament for the prophylaxis or treatment of a disease associated with prolonged ventricular repolarization (cardiac arrhythmia) caused by one or more mutations in the amino acid sequence of the hERG potassium channel.

The present invention discloses application of AMO-134 in preparation of a hERG expression promoting pharmaceutical composition for treating arrhythmia, and a pharmaceutical composition for treating arrhythmia, and the pharmaceutical composition is characterized by containing AMO-134.

The present invention provides compounds of general formula I, isomers thereof, non-toxic pharmaceutically acceptable salts or solvates thereof. The compounds have remarkably strengthened analgesic activity, reduce the acute toxicity obviously, have no inhibition to heart Herg channel, and reduce side effects on coordination movement of mice remarkably. The present invention realizes the separation of activity and side effects, and has a good application prospect.

Disclosed is an anti-coagulant which has extremely excellent inhibitory effect on FXa and an extremely poor inhibitory effect on hERG channel, and can be administered through the oral route. Specifically, disclosed is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof.

The present invention provides methods and compositions relating to an assay for hERG channel protein sensitivity to small molecule pharmacological agents. In one embodiment, the invention includes an engineered hERG channel protein. In another embodiment, the invention includes a method of identifying small molecule pharmacological agents that interfere with repolarization of cardiac cells.

The invention belongs to the field of medicines, and relates to a pharmaceutical composition for treating type 2 long QT syndrome and application thereof. According to the invention, immunoblotting detection is utilized to find that the combined application of the Lurmacatray and the HSF1A has an obvious promotion effect on mature transport of hERG mutant protein, the Lurmacatray and the HSF1A are applied to an HEK-293 cell model transfecting hERG and mutant plasmids of the hERG, and Ikr current generated by an hERG channel is detected by utilizing whole-cell patch forceps, so that the combined application of the Lurmacatray and the HSF1A finds that the current density is obviously increased, and activation gating kinetics of a mutation channel is converted into a wild type, so that the transport of the hERG mutant protein is realized by up-regulating key transport molecular chaperones Hsp70 and Hsp90 by utilizing the combination of the Lurmacatray and the HSF1A, and the aim of treating the type 2 long QT syndrome is fulfilled by promoting the mature transport of the hERG mutant protein.